First clinical demonstration of sustained insulin-like growth factor 1 elevation via oral somatostatin receptor 5 antagonism: a phase 1 trial of SCO-240
Authors' conclusion
Multiple oral doses of SCO-240 elicited selective, sustained, and physiologically regulated activation of the GH-IGF-1 axis without detrimental metabolic effects. These findings highlight SSTR5 as a druggable target and support SCO-240 as a potential first-in-class oral therapy for some forms of GHD.
Study context
- Population
- Healthy Japanese men
- Participants
- 32 men
- Comparison
- Once-daily oral SCO-240 vs placebo for 7 days
Methodological detailsdouble-blind, placebo-controlled, phase 1
- Double-blind
- Placebo-controlled
- Phase 1
Primary result
As reported in the abstract
Serum IGF-1 · day 2 through day 8
- SCO-240 induced a robust, sustained increase in serum IGF-1 across all dose levels, elevated above placebo from day 2 through day 8
- Response driven by enhanced growth hormone (GH) secretion: persistent basal tone and enhanced pulsatility
Further findings
Pharmacokinetics
- Steady-state plasma SCO-240 concentrations achieved by day 2
Other pituitary axes and metabolic parameters
- No alterations in other pituitary axes, fasting glucose, or fasting/postprandial insulin
Safety
- SCO-240 safe and well tolerated; all treatment-emergent adverse events mild and resolved spontaneously
Original publication
First clinical demonstration of sustained insulin-like growth factor 1 elevation via oral somatostatin receptor 5 antagonism: a phase 1 trial of SCO-240. Eur J Endocrinol. Published 7 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →